





Brand & Programme Agendas at a Glance 2026

NextGen Biomed is a platform dedicated to advancing biologics, vaccines, and novel therapeutic approaches — helping deliver life-saving medicines to patients faster.



24 - 25 MARCH 2026 | LONDON, UK

- 1,000+ attendees, 150+ expert speakers, and 5 trailblazing conference programmes – Proteins, Antibodies & ADCs, Peptides, Oligonucleotides, Immunotherapy & Immuno-oncology & Vaccines
- 2-day conference and exhibition with a dedicated workshop day covering the latest engineering case studies, novel computational antibody discovery tools & ADC conjugation chemistry
- Spanning the entire biologics lifecycle - from discovery and design to development, delivery & bioprocessing

R&D Spotlight: ADC Conjugation Chemistry

MAY 2026 | ONLINE

- 150+ experts from top pharma, pioneering biotechs & leading academic labs – including specialists in ADC Discovery, Payload/Linker Chemistry, Bioconjugation
- Gain insights from 2 cutting-edge industry talks, plus an extended solution spotlight with live demo and Q&A
- Fast-paced 1 hour online event spotlighting the latest in enhancing payload linker technology with the target in mind and ADC design

R&D Spotlight: Advanced Analytical Strategies for NextGen Antibodies

24 SEPTEMBER 2026 | ONLINE

- 150+ attendees from leading pharmaceutical companies, innovative biotechs & academic institutions, with job titles including Analytical Development, Quality Control, CQA
- 2 industry presentations built around a solution spotlight presentation, featuring a demonstration and live Q&A
- High-impact 1 hour online meeting covering the latest platform solutions and case studies on high-throughput techniques for biotherapeutics characterisation and developability testing

MARCH

MAY

SEPTEMBER

NextGen Biomed
at a Glance

NextGen Biomed
2026

R&D Spotlight:
ADC Conjugation
Chemistry

R&D Spotlight:
Advanced
Analytical
Strategies
for NextGen
Antibodies

R&D Spotlight:
Enhancing CGT
Bioprocessing
Efficiency

R&D Spotlight:
Computational
Antibody
Discovery


Cell 2026

Editorial & Events
Calendar

LifeScience
Xchange

Enquire





Brand & Programme Agendas at a Glance 2026

NextGen Biomed is a platform dedicated to advancing biologics, vaccines, and novel therapeutic approaches — helping deliver life-saving medicines to patients faster.

R&D Spotlight: Enhancing CGT Bioprocessing Efficiency

07 OCTOBER 2026 | ONLINE

- 150+ R&D leaders from top pharma, trailblazing biotechs, and world-class academic labs, with job titles including Upstream & Downstream Bioprocessing, CGT Development & CGT Manufacturing
- 2 exclusive industry case studies plus an extended solution spotlight with live demo and Q&A
- Power-packed 1 hour online session: explore cutting-edge platform solutions, navigate bioprocessing costs

R&D Spotlight: Computational Antibody Discovery

25 NOVEMBER 2026 | ONLINE

- 150+ attendees from leading pharmaceutical companies, innovative biotechs & academic institutions, with job titles including Antibody Engineering, Biologics Discovery & Bioinformatics
- 2 industry presentations built around a solution spotlight presentation, featuring a demonstration and live Q&A
- High-impact 1 hour online meeting covering the latest platform solutions and case studies on AI/ML-guided antibody engineering, novel discovery platforms & harnessing data to accelerate engineering



12 - 13 NOVEMBER 2026 | LONDON, UK

- 1,000+ attendees and 100+ expert presentations across 12 dynamic content tracks plus a buzzing investor & start up zone
- 2-day conference packed with insights, innovation; plus a hackathon and investment afternoon
- 3 cutting-edge programmes: Cell Culture & Bioprocessing, Advanced Therapy Development and Cell & Gene Therapy Manufacturing
- Covering novel biologics processing and the full advanced therapies value chain from early concept to scalable manufacturing, commercialisation & patient access

OCTOBER

NOVEMBER

NOVEMBER

NextGen Biomed
at a Glance

NextGen Biomed
2026

R&D Spotlight:
ADC Conjugation
Chemistry

R&D Spotlight:
Advanced
Analytical
Strategies
for NextGen
Antibodies

R&D Spotlight:
Enhancing CGT
Bioprocessing
Efficiency

R&D Spotlight:
Computational
Antibody
Discovery


Cell 2026

Editorial & Events
Calendar

LifeScience
Xchange

Enquire





24 - 25 March 2026 | London, UK

The premier event, where the future of biologics takes shape.



1,000+
Leaders, Experts,
and Researchers
Attending



600+
Pre-arranged
1-2-1 Meetings



20 Content
Tracks across
2 Days



Now in its
19th
Year

Bringing the next generation of biomedicines from concept to market

Join leaders, experts, and researchers at **NextGen Biomed 2026**, a premier event that brings together pharmaceutical and biotech representatives, as well as academia, for high-level discussions on the latest innovations in biologics discovery and development.

This conference is an unparalleled opportunity to network with top professionals in the field, share groundbreaking research, and explore cutting-edge advancements that are shaping the future of biologics. Engage in insightful presentations, panel discussions, and workshops designed to foster collaboration and drive progress in the biologics field.

Workshop Day: 23rd March 2026

A high-energy workshop day, diving into next-gen antibody engineering, smarter ADC conjugation, and powerful computational tools driving biologics forward. Three tracks, one goal: faster, smarter, better drug development.


[Visit website](#)

[Enquire: sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)

In-Person Congress & Exhibition Across 5 Programmes



**Proteins,
Antibodies & ADCs**



Peptides



Oligonucleotides



**Immunotherapy &
Immuno-oncology**



Vaccines


Attendee companies to include




Last Year's 1,100+ Attendees at a Glance

880+
Industry, Academic & Healthcare

Seniority of the
Industry, Academic & Healthcare Attendees



310+
Commercial



“The people at NextGen Biomed are knowledgeable, thoughtful, and eager to engage. It's the perfect environment to tackle tough problems and discuss how to collaborate in solving them.”

- RICHARD HAMMOND, CTO, SPHERE FLUIDICS



NextGen Biomed
at a Glance

NextGen Biomed
2026

R&D Spotlight:
ADC Conjugation
Chemistry

R&D Spotlight:
Advanced
Analytical
Strategies
for NextGen
Antibodies

R&D Spotlight:
Enhancing CGT
Bioprocessing
Efficiency

R&D Spotlight:
Computational
Antibody
Discovery



Cell 2026

Editorial & Events
Calendar

LifeScience
Xchange

[Enquire](#)





Proteins, Antibodies & ADCs Programme Overview

24 - 25 March 2026
London, UK

[Enquire](#)

[Visit website](#)

Join leading scientific experts at our annual **Proteins, Antibodies & ADCs** programme, where we explore key strategies, breakthrough science, cutting-edge technologies in protein and antibody engineering and AI/ML in antibody discovery. Discover the latest in bioanalytical techniques, real-world case studies on next-gen biotherapeutics & cell engagers, and innovations across upstream and downstream processing.

VPs, Directors & Senior Managers from leading pharma & biotech companies and research institutions in the following fields and more:

- Antibody Engineering
- Protein Engineering
- Biotherapeutics
- Analytical Development
- Antibody Technologies
- Antibody Discovery
- Protein Purification
- Clinical Development
- Protein Expression

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers:

- Engineering Platforms
- Bioconjugation
- Antibody Generation
- Antibody Humanisation
- Developability Assessment
- Computational Biology
- Bioanalytical Development
- Bispecific Antibody Design
- Expression Systems

2026 Key Speakers include:



CHRISTOPHER HERRING, Vice President of Biology & Safety, **T-Therapeutics**



AGNIESZKA LEWANDOWSKA, Associate Director of Analytical Development, **Immunocore**



DANIËLLE VAN WIJK, Principal Scientist, **Byondis**



LOLKE DE HAAN, Vice President of Toxicology, **ADC Therapeutics**



ANGUS SINCLAIR, Chief Scientific Officer, **LabGenius Therapeutics**



CAROLINE BARELLE, Chief Executive Officer, **Elasmogen**

Day One

Antibody Discovery & Selection: Novel Tools & Technologies

- Addressing difficult targets with display technologies
- Developing novel in vitro display technologies for antibody discovery & engineering
- Antibody selection for poly-specificity & developability

ADC Design, Validation & Optimisation to Enhance Their Therapeutic Potential

- Novel strategies and methods to optimise the design of ADCs
- Linker / payload technologies to achieve better therapeutic index
- Overcoming toxicity challenges

Emerging Analytical Techniques, Developability & Quality Control Systems

- Emerging methods for biologics bioanalysis
- Addressing the challenges of antigenicity
- Immunogenicity & PKPD

Bioprocessing: Upstream Development: Novel Strategies for Cell Line Development & Expression Optimisation

- Transposase mediated cell line generation
- Cell culturing technologies
- Advancing viral vector production through cell line development and engineering

NextGen Multi-Specifics, Cell Engagers & Other New Modalities

- Target identification strategies
- Safety cytokine profiling
- Novel cytokines & functions

Day Two

AI/ML-Guided Protein & Antibody Engineering

- Innovative de novo antibody generation
- Computational and analytical tools for protein engineering
- High-throughput & low-throughput methods: application of AI/ML & deep learning tools in antibody engineering
- Computational epitope – paratope mapping & epitope mapping

ADC Pre-Clinical & Translational Development

- Understanding toxicity mechanisms
- Case studies from using ADCs for treatment of solid tumours
- Characterising ADC safety in short preclinical studies
- Preclinical & translational development of ADCs across in vitro & in vivo models

Analytical Development: Stability & In-Depth Characterisation Methods for Proteins & Antibodies

- Stability testing
- Characterisation with Advanced chromatography techniques / Mass spec / Hybrid LCMS / Capillary electrophoresis (CE)

Day 2 Track 4: Downstream Development: Protein Purification & Recombinant Protein Production

- Novel purification methods
 - Developing and optimising high-throughput purification methods to increase efficiency
- Digital twins to optimise purification processes
- Innovations in recombinant protein production: automation

NextGen Biomed
at a Glance

NextGen Biomed
2026

R&D Spotlight:
ADC Conjugation
Chemistry

R&D Spotlight:
Advanced
Analytical
Strategies
for NextGen
Antibodies

R&D Spotlight:
Enhancing CGT
Bioprocessing
Efficiency

R&D Spotlight:
Computational
Antibody
Discovery


Cell 2026

Editorial & Events
Calendar

LifeScience
Xchange

[Enquire](#)





Peptides Programme Overview

24 - 25 March 2026
London, UK

[Enquire](#)

[Visit website](#)

Our **Peptides** programme brings together leading experts in peptide chemistry and therapeutic development. As cutting-edge technologies continue to drive the field forward, join us in London to connect, exchange ideas, and explore the key challenges and emerging opportunities shaping the future of peptide science.

VPs, Directors & Senior Managers from leading pharma & biotech companies and research institutions in the following fields and more:

- Peptide Chemistry
- Green Materials
- Peptide Therapeutics
- Medicinal Chemistry
- Computational Biology
- Peptide Analysis
- Process Development
- Peptide Manufacturing
- Peptide Discovery

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers:

- Peptide Synthesis
- Peptide Analysis
- Peptide Sequencing
- Peptide Modifications
- Reagents
- Peptide Libraries
- Peptide Production
- Peptide Delivery
- Peptide Design

2026 Key Speakers include:



HANNAH BOLT,
Head of Peptide
Discovery, Director,
AstraZeneca



ELISABETTA BIANCHI,
Director of Discovery
Chemistry,
Curium Pharma



MARK ECCLESTON,
Chief Executive Officer,
ValiRx



CÉCILE BROCARD,
Director Downstream
Development,
Boehringer Ingelheim



LUKAS LEDER,
Senior Principal
Scientist,
Novartis



FERNANDO ALBERICIO,
Professor,
**University of KwaZulu-
Natal**

“I've had really good interactions with people using and interested in my technology. That's why we come here - to discuss how we develop products of the future and understand the challenges the industry has”

- STEPHEN LOCK, SENIOR MARKET DEVELOPMENT MANAGER, BIOPHARMA, EMEA, SCIEX



Day One


Peptide Discovery & Green Chemistry

- Advancements in mass spec methods:
 - » Quantitative proteomics
 - » De novo sequencing
- Peptide characterisation
- Advanced analytical QC methods for peptides
- Peptide sequencing
- AI/ML for therapeutic analytics
- Peptide display & de novo peptide sequencing
- Peptide chips
- Advanced computational methods & tools:
 - » Implementing AI/ML
 - » Cheminformatics
 - » Deep generative models for peptide design
- Advanced peptide synthesis & high-throughput purification methods: making peptides recombinantly

Day Two

Peptide Therapeutics & Development

- Long-acting injectable technologies
- Peptide design for various therapeutic targets
- Discovery & optimisation of peptide therapeutics
- Peptide characterisation to support therapeutic applications:
 - » Novel technologies & techniques
 - » Advanced structures
 - » Cosmetic peptides



Oligonucleotides Programme Overview

24 - 25 March 2026
London, UK

[Enquire](#)

[Visit website](#)

Join key opinion leaders ushering in a new era of innovation in oligonucleotide discovery and therapeutics. Presentations will cover computational approaches, methods, and tools for oligonucleotide CMC, along with analytical control strategies and green synthesis approaches, highlighting advancements in bringing the next generation of oligo-based therapies to market.

VPs, Directors & Senior Managers from leading pharma & biotech companies and research institutions in the following fields and more:

- Oligo Discovery
- Oligo Analysis
- Oligo Therapeutics
- Oligo Chemistry
- Medicinal Chemistry
- RNA Therapeutics
- Therapeutics Development
- Discovery Chemistry
- Oligo Delivery

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers:

- Oligo Synthesis
- Oligo Conjugation
- Oligo Modification
- Oligo Purification
- Mass Identification
- Stability Testing
- DNA & RNA Oligos
- Oligo Analysis
- Oligo Production

2026 Key Speakers include:



ANDERS GABRIELSEN,
Vice President & Head
of Global Clinical
Development, **Ribocure
Pharmaceuticals AB**



ALESSANDRA
TOLOMELLI,
Associate Professor,
University of Bologna



MARIA LEVITIN,
Director of RNA
Oligonucleotide Delivery,
Genetic Medicine,
Grünenthal



ANNA PERDIX,
Chief Executive Officer,
Sixfold Bioscience



ANNABELLE BISCANS,
Director,
AstraZeneca



MARIA LILJEVALD,
Head of Global
Regulatory
Affairs, **Ribocure
Pharmaceuticals AB**

Day One

Oligonucleotide Discovery & Green Chemistry

- Computational approaches, methods & tools
 - » AI/ML & computational chemistry
 - » Oligonucleotide drug design & characterisation
- Rapid screening analytical methods
- Lead candidate optimisation
- Novel chemistry approaches & new backbone modifications
- Latest developments in oligonucleotide green manufacturing:
 - » Large-volume manufacturing
 - » Alternative synthesis technologies
- Oligo green large scale synthesis updates
- Impurity analysis & methods to understand impurity profiles
- Analytical control strategies for oligonucleotides
- Developability assessment

Day Two

Oligonucleotide Therapeutic Development & Optimisation

- Case studies: successes from therapeutics
 - » Oncology, neuroscience, cardiometabolic indications, rare disease, immunology
- Progress to clinical trials: siRNA, microRNA, saRNA, ASO
- Oligonucleotide delivery and targeting:
 - » Labelling & imaging
 - » Oligonucleotide conjugates
 - » Unconjugated & extrahepatic delivery
- Pharmacology considerations
 - » Immunogenicity considerations for oligonucleotides
- Drug to drug considerations
 - » Safety pharmacology
 - » Non-clinical pharmacology
 - » PKPD & modelling



I gave a talk earlier today and the audience was so receptive: people have come to me and asking questions afterwards. It facilitates not only positive movements for the business and finance, but also for science as a whole."

- JOSEPH DENBY, SENIOR MANAGER
BUSINESS DEVELOPMENT EUROPE,
CPC SCIENTIFIC





Our immunotherapy-focused programme brings together thought leaders sharing case studies, novel approaches, and high-level strategy presentations on the current landscape and pressing challenges in immunotherapy development. Featuring the latest technological insights – including biomarker discovery and multi-omics technologies – don't miss this opportunity to join us and stay ahead of the curve.

VPs, Directors & Senior Managers from leading pharma & biotech companies and research institutions in the following fields and more:

- Immunotherapy
- Immuno-Oncology
- Translational Medicine
- Cell Therapy
- Cancer Vaccines
- Clinical Development
- Biomarkers Identification
- Biomarker Technologies
- Multi-Omics

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers:

- Immunotherapy Platforms
- Biomarker Validation
- Single Cell Technologies
- Animal Models
- Checkpoint Marker Detection
- Target Validation
- Lead Identification
- Antigen Discovery
- Immunobiology

2026 Key Speakers include:



JOHN BRIDGEMAN,
Chief Scientific
Officer,
Immuno Key



SONIA MACIA,
Chief Medical Officer,
Aromics Therapeutics



SIMON PLYTE,
Chief Scientific Officer,
**Biomunex
Pharmaceuticals**



ANNELISE VUIDEPOT,
Chief Technology
Officer, Research &
UK Site Lead,
Immunocore



HANS VAN DER VLIET,
Chief Scientific Officer,
LAVA Therapeutics



LIVIJA DEBAN,
Chief Scientific Officer,
Prokarium

Day One

Discovery & Development of Therapies for Cancer & Autoimmune Diseases

- Cell-based therapeutics: CAR-T, CAR-NK cell therapies
- Challenges in advancing IO therapies
- Personalised cell therapy & cancer neoepitopes
- Anti-T cell therapies: CD3, CD19, CD20, and others
- T-cell or APC-specific therapies

Biomarker-Driven Personalised Immunotherapy

- Biomarker strategies in the era of PD-1 checkpoint combination therapies
- Development & delivery of personalised immunotherapy
- New biomarker technologies in the prediction of response
- Technologies for biomarker development of patient populations
- Patient selection & stratification for immuno-oncology

Next-Generation Targets & Emerging Therapeutic Platforms

- Novel target identification and validation strategies, methods
- Emerging technological approaches & strategies:
 - » High-throughput screening
 - » Computational biology
 - » Genomic sequencing
 - » CRISPR
- Exploring new immune checkpoint targets: TIGIT / LAG-3 / VISTA
- Recent progress: immune checkpoint inhibitors
- Targeting the PD-1 pathway and finding alternative therapeutic targets

Day Two

Bridging the Gap From Discovery to Clinical Outcomes: Imaging, Modelling, Liquid Biopsy & Combination Strategies


- Innovations in imaging technologies (e.g., PET, MRI, and advanced CT scans) for monitoring tumour dynamics and immunotherapy response in real-time
- Non-invasive imaging to assess immune cell infiltration and efficacy of combination therapies
- Use of patient-derived tumor organoids and 3D culture systems to simulate tumor microenvironments for drug screening and combination therapy testing

Multi-Omics & Spatial Technologies in Immuno-Oncology

- Multi-omics technologies in IO
- Utilisation of spatial technologies in immuno-oncology
- Genetic analysis technologies for immuno-oncology research
- NextGen & single cell sequencing
- Digital pathology for immuno-oncology

Translational Models in Immuno- Oncology: In Vitro & In Vivo Approaches

- Maximising translatability through effective in vitro and in vivo models
- Humanised & 3D mouse models
- Choosing the right preclinical models for assessing safety and efficacy
- Technologies to transition from animal testing
- Non-clinical approaches for predicting single agent vs combination value



Vaccines Programme Overview

24 - 25 March 2026
London, UK

Enquire

Visit website

Our Vaccines programme unites leading experts pioneering the next generation of vaccines for infectious diseases. It delivers cutting-edge presentations and lively panel discussions on breakthrough vaccine platforms, AI-driven design innovations, and advanced development and analytical strategies. Join us to explore how technology and science are reshaping vaccine discovery and accelerating global health solutions.

VPs, Directors & Senior Managers from leading pharma & biotech companies and research institutions in the following fields and more:

- Vaccines R&D
- Vaccine Design
- Computational Vaccinology
- Vaccine Analytics
- Viral Vaccines Development
- mRNA-based Antigen Design
- Process Development
- Translational Research
- Vaccine Bioinformatics

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers:

- Vaccine Platforms
- Adjuvant Selection
- Vaccine Assays
- Delivery Systems
- Vaccine Assessment
- Characterisation
- Vaccine Testing
- Vaccine Safety
- AI/ML

2025 Key Speakers included:



BRIAN SCHANEN,
Global Head Of
Biomarkers,
Sanofi



ASHLEY OTTER,
Principal Investigator,
**UK Health Security
Agency**



TOMASZ WITKOS,
Associate Director,
AstraZeneca



CALLUM SCOTT,
Head Of
Development,
Scancell



TREVOR SMITH,
Vice President,
Inovio Pharmaceuticals



IULIA OITA,
CMC Head of Analytics,
Ziphys Vaccines NV

Day One

Vaccine Platforms & AI-Driven Design Approaches

Part 1 – Nucleotides-Based Platforms

- Overview of modern vaccine technologies:
 - » mRNA
 - » New DNA vaccines
- Developing the next generation of vaccine platforms
- Advancing antigen development for advanced vaccine platforms:
 - » Novel antigenic targets for vaccines
 - » Predicting antigenic epitopes
 - » Advances in antigen design
 - » Antigen selection
 - » Combination & multivalent vaccines
 - » Strategies to combine multiple antigens for broader protection (e.g., mRNA-based and alternative vaccine platforms suited for combos)

Part 2 – Biologics & Other Vaccine Platforms

- Live-attenuated vaccines
- Inactivated vaccines
- Subunit vaccines
- Toxoid vaccines
- Viral vector-based vaccines
- AI-driven vaccine design
 - » Identify novel epitopes and optimise immunogenicity / signatures of reaction to inform on screening and next gen vaccine designs

Day Two

Translational & Clinical & AI-Driven Vaccine Development

- Biomarkers studies from mRNA vaccines evaluation
- Failures in vaccine development
- Immuno-reactogenicity of mRNA vaccines
- The seasonal flu mRNA vaccines under development
- Other than Flu/SARS CoV2 infectious target using mRNA vaccines
- New cell-specific targeting approaches
- Data science from mRNA vaccines development and results (AI/ML)
- Pandemic preparedness
- mRNA cancer vaccines
- Viral vaccines for cancer (HPV, EBV)
- Intranasal and mucosal vaccines
 - » Enhancing protection at entry points of infection

Vaccine Analytics, Stability & Delivery for Infectious Diseases

- Gene expression testing
- Lab automation for mRNA vaccines screening
- Stability testing, cold chain reduction strategies
- Cell-based assay development
- mRNA vaccine cell biology mechanistic and pathways
- Routes of administration (e.g. intranasal routes)
- PRR and RLR binding assays
- Vaccine efficacy testing
- Endosomal escape assays
- Synthetic biology & cell-free vaccine production
- Preclinical In vitro and in vivo imaging
- Computational approaches, methods & tools
 - » Codon optimization design
 - » UTR optimization

NextGen Biomed
at a Glance

NextGen Biomed
2026

R&D Spotlight:
ADC Conjugation
Chemistry

R&D Spotlight:
Advanced
Analytical
Strategies
for NextGen
Antibodies

R&D Spotlight:
Enhancing CGT
Bioprocessing
Efficiency

R&D Spotlight:
Computational
Antibody
Discovery

Cell 2026

Editorial & Events
Calendar

LifeScience
Xchange

Enquire



R&D SPOTLIGHT: ADC Conjugation Chemistry

MAY 2026 | ONLINE

Interest in ADCs has surged in recent years. With 13 FDA-approved therapies and billions of dollars invested in the field, biologics manufacturers must stay focused and avoid getting caught up in the hype.

Join us to explore the latest advances in ADC bioconjugation chemistry, including how enhanced linker technologies can be optimised, the expansion of potential targets, and the use of deep learning for ADC prediction. Witness cutting-edge technologies in action and join a live expert discussion.

- ✓ **Discover Cutting-Edge ADC Bioconjugation Strategies** - Learn how enhanced linker technologies and an expanded pool of targets are advancing the design of next-generation ADCs.
- ✓ **See Innovative Technologies in Action** - Explore how deep learning and other computational approaches are transforming ADC prediction and optimisation.
- ✓ **Connect Live with Experts** - Engage directly with leading scientists, solution providers, and thought leaders shaping the future of ADC development.

VPs, Directors & Senior Managers from leading pharma & biotech companies and research institutions in the following fields and more:

- ADC Discovery
 - Payload/Linker Chemistry
 - Bioconjugation
- Antibody Discovery
 - Antibody Engineering
 - ADC Development



R&D SPOTLIGHT:

Advanced Analytical Strategies for NextGen Antibodies

24 SEPTEMBER 2026 | ONLINE

Antibodies are versatile but must meet key attributes for scalable, safe therapeutics.

While standard developability assays guide mAb design, next-generation formats demand smarter, more targeted characterisation. This session will also showcase high-throughput ADC characterisation, focusing on free drug levels to accelerate development.

- Gain Cutting-Edge Insights - Learn the latest analytical approaches to characterise standard and next-generation antibodies.
- Accelerate Development Decisions - Discover how high-throughput and targeted assays can guide developability and optimise therapeutic design.
- Engage with Experts - Connect with leading scientists and thought leaders driving innovation in antibody characterisation.

VPs, Directors & Senior Managers from leading pharma & biotech companies and research institutions in the following fields and more:

- Analytical Development
 - Quality Control
 - CQA
- Antibody Characterisation
 - Developability Assessment
 - Assay Development



How It Works

Our R&D Spotlights are created to bring together targeted and specialised industry representatives from different geographies, with a desire to knowledge-share, network and educate themselves on potential services and solutions.

This online event will be promoted to contacts in relevant databases through dedicated e-mails, targeted newsletters and focussed posts on our social media channels, with sponsors afterwards receiving all contact details of registrants.

Showcases are delivered through **LifeScienceXchange**, our bespoke content delivery platform.



Visit LifeScienceXchange

Enquire

Sample Agenda	
14:00 - 14:15	Industry Presentation: New Frontiers In Rationalising Mabs Developability Testing DAVID BROCKWELL, Professor, University of Leeds
14:15 - 14:30	Industry Presentation: Revolutionising ADC Characterisation With High Throughput Techniques SARAH HINDSON, Scientific Investigator, GSK
14:30 - 14:45	Solution Provider Presentation For sponsorship opportunities please contact sponsorship@oxfordglobal.com
14:45 - 15:00	See The Technology In Action + Live Q&A
End of Technology Showcase	

R&D SPOTLIGHT: Enhancing CGT Bioprocessing Efficiency

07 OCTOBER 2026 | ONLINE

Discover the latest breakthroughs in cell & gene therapy bioprocessing.


Explore the latest innovations in cell and gene therapy bioprocessing at this focused tech showcase. Learn about strategies to enhance efficiency and streamline purification, as well as approaches to overcome common challenges in large-scale CGT manufacturing. Attendees will see cutting-edge technologies in action and join a live expert discussion on practical applications, implementation strategies, and solutions for advancing bioprocessing.

- ✓ **Stay Ahead of Innovation** - Gain insights into the latest technologies and strategies shaping CGT bioprocessing.
- ✓ **Practical Solutions** - Learn how to tackle real-world challenges in large-scale production and streamline workflows.
- ✓ **Expert Interaction** - Engage directly with industry leaders during live discussions to explore applications, best practices, and emerging trends.

VPs, Directors & Senior Managers from leading pharma & biotech companies and research institutions in the following fields and more:

- Upstream Bioprocessing
 - Downstream Bioprocessing
 - CGT Development
- CGT Manufacturing
 - MSAT
 - CMC

4,500+ Marketable Contacts



How It Works

Our R&D Spotlights are created to bring together targeted and specialised industry representatives from different geographies, with a desire to knowledge-share, network and educate themselves on potential services and solutions.

This online event will be promoted to contacts in relevant databases through dedicated e-mails, targeted newsletters and focussed posts on our social media channels, with sponsors afterwards receiving all contact details of registrants.

Showcases are delivered through **LifeScienceXchange**, our bespoke content delivery platform.



- Visit LifeScienceXchange
- Enquire

Sample Agenda

14:00 - 14:15	Industry Presentation: Early Beginnings: Using AI-Based Tools For Optimisation & Functional Engineering Of Antibody Candidates BERIT OLSEN KROGH, Senior Research Fellow, Lundbeck
14:15 - 14:30	Industry Presentation: AI Models Revolutionising Antibody Structure and Sequence Design PHILIP KIM, Professor, University of Toronto
14:30 - 14:45	Solution Provider Presentation For sponsorship opportunities please contact sponsorship@oxfordglobal.com
14:45 - 15:00	See The Technology In Action + Live Q&A

End of Technology Showcase

NextGen Biomed at a Glance

NextGen Biomed 2026

R&D Spotlight: ADC Conjugation Chemistry

R&D Spotlight: Advanced Analytical Strategies for NextGen Antibodies

R&D Spotlight: Enhancing CGT Bioprocessing Efficiency

R&D Spotlight: Computational Antibody Discovery

Cell 2026

Editorial & Events Calendar

LifeScience Xchange

Enquire



R&D SPOTLIGHT:

Computational Antibody Discovery

25 NOVEMBER 2026 | ONLINE

Explore cutting-edge advancements in computational antibody discovery platforms, featuring real-world case studies on AI/ML in antibody engineering.

Learn the latest updates on data generation and normalisation to support effective AI integration. Attendees will witness breakthrough tech firsthand, followed by an interactive expert panel exploring practical uses and key challenges.

- ✓ **Unlock the Power of AI in Antibody Engineering** - Gain insights into how AI and machine learning are transforming antibody discovery, optimisation, and design.
- ✓ **Learn from Real-World Case Studies** - Explore practical applications of computational platforms and see how industry leaders are leveraging data-driven approaches to accelerate innovation.
- ✓ **Stay Ahead with Data-Driven Strategies** - Discover best practices for data generation and normalization to enhance the accuracy and effectiveness of AI-powered discovery tools.

VPs, Directors & Senior Managers from leading pharma & biotech companies and research institutions in the following fields and more:

- Antibody Discovery
 - Bioinformatics
 - Computational Tools
- Antibody Design
 - Protein Engineering
 - Biologics Discovery





12 - 13 November 2026 | London, UK

 **1,000+**
Leaders, Experts, and
Researchers Attending

 **600+**
Pre-arranged
1-2-1 Meetings

 **20** Content Tracks
across **2 Days**

 Now in its
19th Year

**2025's Registered
Attendees
at a Glance**



Connecting leaders from every stage of the value chain to drive advanced therapy development & novel biologics processing.

Join top experts and innovators at **Cell 2026** – the leading event for bioprocessing and advanced therapies. Connect with pharma, biotech, academia, and regulators across the full cell culture and cell & gene therapy lifecycle.

From discovery to commercialisation, explore breakthrough technologies, share game-changing science, and build impactful collaborations. Stay ahead of trends, tackle challenges, and fast-track your path from lab to market – all in one essential event.

In-Person Congress & Exhibition
Across 3 Comprehensive Programmes



**Cell Culture &
Bioprocessing**



**Advanced Therapy
Development**



**Cell & Gene Therapy
Manufacturing**

[Visit website](#)

[Enquire: sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)

Attendee companies to include

AstraZeneca

BlueRock
Therapeutics

MHRA
Regulating Medicine and Medical Devices

Adaptimmune
TRANSFORMING T CELL THERAPY

novo nordisk

Pfizer

Rinri
Therapeutics
Hearing. Restored.

TreeFrog
therapeutics

2025's Keynote Speakers included






BOBBY GASPAR,
Co-Founder & Chief
Executive Officer,
Orchard Therapeutics



CHRISTOF VON KALLE,
Director, BIH & Charité Clinical
Study Center BIH Chair for Clinical
and Translational Sciences Director,
Research Clinic Luxemburg



DAME MOLLY STEVENS,
John Black Professor of
Bionanoscience,
University of Oxford



**Seniority of the Industry, Academic &
Healthcare Attendees:**

30% - Scientist

47% - Head / Lead / Manager / Senior

23% - Director & C-Level

“For me, the biggest highlight has been the interaction with the customers. We’ve met quite a few new customers or potential customers as well as existing ones, and also we’ve been able to raise the profile of our products. The fact that we’ve been able to arrange meetings have been really beneficial in doing that.”

- STEPHEN ROBINSON, PRODUCT MANAGER,
AIR PRODUCTS (SPONSOR OF THE 2024 EVENT)



NextGen Biomed
at a Glance

NextGen Biomed
2026

R&D Spotlight:
ADC Conjugation
Chemistry

R&D Spotlight:
Advanced
Analytical
Strategies
for NextGen
Antibodies

R&D Spotlight:
Enhancing CGT
Bioprocessing
Efficiency

R&D Spotlight:
Computational
Antibody
Discovery

Cell 2026

Editorial & Events
Calendar

LifeScience
Xchange

[Enquire](#)





Cell Culture & Bioprocessing Programme Overview

November 2026
London, UK

[Enquire](#)

[Visit website](#)

Our **Cell Culture & Bioprocessing Programme** is where innovation meets real-world application. Explore advances in iPSC integration, 2D vs. 3D culture impacts, and learn from case studies highlighting breakthroughs and challenges. Discover cutting-edge strategies to streamline cell line development, enhance clone screening, and boost predictability, driving efficiency and removing bottlenecks in bioprocessing.

VPs, Directors & Senior Managers from leading pharma & biotech companies and research institutions in the following fields and more:

- Cell Culture
- Cell Line Engineering
- Cell Line Development
- Upstream Bioprocessing
- Downstream Bioprocessing
- Automation
- Cellular Operations
- Cell Banking
- ATMP

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers:

- Cell Culture Media
- Cell Culture Supplements
- Automation
- Bioreactors
- Single-Use Systems
- Flow Cytometry
- Process Monitoring Tools
- Bioprocessing Solutions
- Pre-Clinical Solutions

Key speakers for the 2026 event include:



JOSHUA BAGLEY
Chief Scientific Officer,
a:head bio



LYDIA CARO,
Associate Director,
Cell Sciences,
Ichnos Sciences
Biotherapeutics SA



GUIQIN WU,
MSAT Scientist USP,
Sanofi



AMELIA LANE,
Director of Preclinical
Development,
MeiraGTx



MELISSA BARR,
Head of Scientific
Operations,
ValiRx



LEILA ABBAS,
Preclinical Lead,
Rinri Therapeutics

Day One

Cell Line Engineering Ensuring Stability, Quality & Clonality

- Improving efficiency and removing bottlenecks in cell line development
- Clone selection strategies and establishing monoclonality
- Screening clones for productivity and titer
- Strategies for single-cell isolation
- Predicting & characterizing clones
- Improving the stability of cell lines via optimized transfection
- Gene delivery & editing for cell line development

Upstream Bioprocessing

- High throughput technologies in bioprocessing
 - » Automation & robotics
 - » Software & AI
- Improving instrumentation for biopharmaceutical drug production
- Bioreactors & perfusion systems
- Leveraging ADC's to streamline drug production processes
- Online monitoring techniques
 - » Online sensors for cell culture
- Scale up
- Manufacturing biopharmaceuticals with microbial systems
- Challenges in replacing human components

Day Two

Innovations in Pre-Clinical Assay Development, Cell Culture Media Optimisation & 3D Cultures: From In Vitro Models to Translational Success

- Advances in 3D cultures and their role in translational research
- Integration of iPSC models for pre-clinical studies
- Strategies to progress research with or without animal models.
- Case studies highlighting successes and failures
- Real-world examples of assay development and validation
- Insights into gene target validation and optimization
- Optimizing cell culture & media development:
- Techniques for enhancing cell culture productivity
- Media development, analysis, and regulatory considerations.
- Lessons from cellular agriculture and supply chain challenges.
- Integration of cryopreservation techniques and toxicology evaluations in pre-clinical assays
- 2D vs. 3D cultures

Downstream Bioprocessing

- Data for downstream processing
- PAT tools for predictivity
- Facilitating technology transfer for cell-based products
- Reducing timelines in bioprocessing
- Host cell proteins & removing impurities

NextGen Biomed
at a Glance

NextGen Biomed
2026

R&D Spotlight:
ADC Conjugation
Chemistry

R&D Spotlight:
Advanced
Analytical
Strategies
for NextGen
Antibodies

R&D Spotlight:
Enhancing CGT
Bioprocessing
Efficiency

R&D Spotlight:
Computational
Antibody
Discovery

Cell 2026

Editorial & Events
Calendar

LifeScience
Xchange

[Enquire](#)





Advanced Therapy Development Programme Overview

November 2026
London, UK

[Enquire](#)

[Visit website](#)

Advance the future of medicine at our Advanced Therapy Development Programme, where gene and cell therapy leaders unite to shape what's next. Explore the latest in vector design, gene editing, analytics, AI-driven quality control, clinical trials, and regulatory strategy. From iPSC and stem cell innovation to next-gen CGT case studies and tissue engineering, gain insights across discovery, development, and clinical translation – accelerating your impact in advanced therapies.

VPs, Directors & Senior Managers from leading pharma & biotech companies and research institutions in the following fields and more:

- Cell Therapy
- Gene Therapy
- Regenerative Medicine
- Clinical Development
- Stem Cell Therapy
- Pre-Clinical Assessment
- Regulatory Affairs
- CGT Analytics
- CGT Development

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers:

- Off-The-Shelf Therapies
- Preclinical Testing
- Clinical Trial
- Safety
- Commercial Readiness
- iPSCs
- In Vivo Models
- Functional Assays
- Viral Vectors

Key speakers for the 2026 event include:



JACQUELINE BARRY,
Chief Clinical Officer,
**Cell and Gene Therapy
Catapult**



VICTOR HERNANDEZ,
Chief Scientific Officer,
Axovia Therapeutics



MARCELO RIVOLTA,
Chief Scientific Officer
& Founder Director,
Rinri Therapeutics



RUBEN RIZZI,
Senior Vice President
Global Regulatory
Affairs,
BioNTech SE



STEPHAN KRAUSE,
Executive Director,
Analytical Science
and Technology, Cell
Therapy Quality, **BMS**



KIRSTY SHARPLIN,
Transplant Physician &
Medical Director,
John Radcliffe Hospital

Day One

Gene Therapy Discovery & Development

- Vector engineering: designing and optimizing viral and non-viral vectors for efficient therapeutic delivery
- Next-gen strategies: gene editing technologies
- Preclinical validation, assessing safety and efficacy, including off-target effects

Cell & Gene Therapy Analytics & Quality Control

Part 1 – Cell Therapy Analytics

- Raw material management
- Analysing and monitoring processes to ensure product quality
- Starting materials, process control
- Characterising cell-based therapies
- Incorporation of omics, AI/ML to close the gaps in data
- Novel approaches to cell culture process control strategies
- Quality control
- Formulation development with AI/ML

Part 2 – Gene Therapy Analytics

- Vector characterisation
- Gene expression analytics
- Formulation development with AI/ML & overcoming stability & characterisation challenges

Viral & Non-Viral Gene Delivery of Gene Therapies

- Targeted delivery approaches
- Viral vectors: AAV, lentivirus, adenovirus
- Non-viral systems: LNPs, polymers, exosomes, electroporation, nanoparticles
- Delivery of DNA, RNA, mRNA, siRNA, and CRISPR gene-editing components

Day Two

Cell Therapy Discovery & Development

- NK, TCR, Innate Killer Cell Therapies
- Combination therapies for immunotherapeutic response
- Cell therapies for solid tumours & blood-based cancers
- Delivering stem cell therapies from discovery to the clinic
- Stem cell discovery & development: neurodegenerative & cardiovascular diseases, paediatrics

Clinical Development & Clinical Trials For Cell & Gene Therapies

- Defining a clinical trial strategy for CGT therapies
- From bench to bedside-translational case studies
- Improving CAR-T potency for solid tumours
- Effective testing, validation, and characterization approaches: flow cytometry, immunohistochemistry, cytokine profiling, immunogenicity, and genomics
- Patient engagement in clinical trials and patient-centred clinical trial design

Patient Access, Advocacy & Translational Strategies for Advanced Therapies

- Integrating patient voice into discovery, development & clinical planning
- Understanding patient journeys and burden of treatment
- Innovative routes to patient access (specials licences, IITs, US state pathways)
- Affordability, reimbursement models & payer expectations for ATMPs
- Health-economic considerations: value, cost, pricing strategies

NextGen Biomed
at a Glance

NextGen Biomed
2026

R&D Spotlight:
ADC Conjugation
Chemistry

R&D Spotlight:
Advanced
Analytical
Strategies
for NextGen
Antibodies

R&D Spotlight:
Enhancing CGT
Bioprocessing
Efficiency

R&D Spotlight:
Computational
Antibody
Discovery

Cell 2026

Editorial & Events
Calendar

LifeScience
Xchange

[Enquire](#)





Cell & Gene Therapy Manufacturing Programme Overview

November 2026
London, UK

[Enquire](#)

[Visit website](#)

Gain insights into scalable strategies, AI-driven automation, supply chain solutions, and the latest in regulatory and commercialization approaches. With expert sessions on vector production, digitalisation, cryopreservation, and autologous vs. allogeneic platforms, this is your chance to tackle key challenges in bringing CGT therapies from R&D to the clinic—and shape the future of scalable, sustainable, and patient-focused manufacturing.

VPs, Directors & Senior Managers from leading pharma & biotech companies and research institutions in the following fields and more:

- Gene Therapy Manufacturing
- Cell Therapy Manufacturing
- Supply Chain
- Process Development
- Viral Vector Manufacturing
- Commercialisation
- CMC Development
- CGT Production
- Regulatory Affairs

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers:

- Supply Chain Logistics
- Process Analytical Technology
- GMP Manufacturing
- Process Improvement
- Automation
- Cold Chain
- Vector Design
- Cell Processing
- AI & Automation

Key speakers for the 2026 event include:



BEN WEIL
COO, Chief
Manufacturing Officer
**INmuneBio
International**



HOLLIE BARTLEY,
Director, Process
Development,
**Resolution
Therapeutics**



ULRICH RÜMENAPP,
Senior Biotech Program
Lead,
Bayer



MARK PISKADLO,
Vice President, Cell
Therapy Manufacturing,
BMS



LILIAN HOOK,
Director Cell, Apheresis
& Gene Therapies,
**NHS Blood &
Transplant**



LAURA DEEDIGAN,
Head of Analytical
Sciences,
Lift Biosciences

Day One

End-to-End Strategies for Cell & Gene Therapy Manufacturing, Supply Chain & Commercialisation

- Advances in scale-up, continuous processing & sustainable manufacturing
- Quality by Design, single-use technologies & digital twin integration
- Next-generation vector & LNP production platforms for optimised yield
- Bridging R&D to clinical and commercial manufacturing
- Cold chain, cryopreservation & next-gen shipping/tracking innovations
- Regulatory requirements across manufacturing, storage & global transport
- Supply chain optimisation: routing, inventory management & strategic partnerships
- Commercialisation pathways for CGTs, including off-the-shelf therapies
- IP strategy, competitive positioning & global market expansion
- Patient-centred launch planning, reimbursement & market access
- Automation & AI
- Regulatory-compliant validation of AI/ML systems

Day Two

Strategies & Challenges for Cell Therapy Manufacturing, Supply Chain & Commercialisation

- Autologous vs. allogeneic products
- Transitioning to cGMP manufacturing
- Regulatory insights and compliance considerations
- Ensuring sustainable product pipeline
- Analytical techniques: quality control and assurance
- Automation and digitisation in cell therapy manufacturing to enhance efficiency and quality: ML and data analytics
- Transitioning from R&D to clinical manufacturing: navigating the path to commercialisation
- Platform concepts – how CAR-Ts can be manufactured & streamlining the pipelines
- Sustainable manufacturing
- Automation & AI
- GMP expectations and best practices for AI-enabled decision support

NextGen Biomed
at a Glance

NextGen Biomed
2026

R&D Spotlight:
ADC Conjugation
Chemistry

R&D Spotlight:
Advanced
Analytical
Strategies
for NextGen
Antibodies

R&D Spotlight:
Enhancing CGT
Bioprocessing
Efficiency

R&D Spotlight:
Computational
Antibody
Discovery

Cell 2026

Editorial & Events
Calendar

LifeScience
Xchange

[Enquire](#)





Patients are counting on your R&D community for the next wave of life-saving medicines.

LifeScienceXchange is the catalyst: a platform for leaders from diverse life science disciplines to connect, learn and collaborate, so that together we bring new treatments to patients faster, sustainably and at scale.

Providing actionable market insight, R&D Spotlights, thought leadership and essential news, all in a condensed and curated video format.

It will help you understand trends, benchmark your work, inform strategy and ultimately get your new treatments to patients, faster.

LifeScienceXchange.com



CUTTING EDGE SCIENCE DIRECT TO YOUR INBOX



MARKET INSIGHTS

Learn faster and put new ideas to work.

Market Insights unlock key learnings and actionable ideas from our industry-leading live events.

We've cut and curated more than 6,000 hours of live recordings into quick-watch cuts, so you can get straight to the moments that matter.



R&D SPOTLIGHT

Innovate sooner and benchmark success.

Our R&D Spotlights give you first sight of the breakthroughs driving our industry. We put you in touch with new developments and vendor success stories, so you can understand the tech, connect with the innovators and benchmark your work against the best.



THOUGHT LEADERSHIP

Learn and share ideas with industry leaders.

Our Thought Leadership opportunities put you at the heart of the conversations accelerating life sciences R&D today.

Hear interviews and presentations with key opinion leaders each month — and join the conversation by putting your questions to them live.



WEEKLY NEWS

Get the full picture faster.

Our Weekly News digest clarifies and condenses the key developments and talking points in life sciences R&D.

Each week we identify and summarise the five top stories in quick-read format, so you have a full, clear and balanced picture.

NextGen Biomed
at a Glance

NextGen Biomed
2026

R&D Spotlight:
ADC Conjugation
Chemistry

R&D Spotlight:
Advanced
Analytical
Strategies
for NextGen
Antibodies

R&D Spotlight:
Enhancing CGT
Bioprocessing
Efficiency

R&D Spotlight:
Computational
Antibody
Discovery

Cell 2026

Editorial & Events
Calendar

LifeScience
Xchange

Enquire

